Skip to content

Arwr stock zacks


ARWR Description — Arrowhead Pharmaceuticals Inc. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, Co.'s therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders. Arrowhead Pharmaceuticals, Inc. (ARWR) had Net Income of $-19.84M for the most recently reported fiscal quarter, ending 2020-03-31. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share. The drug developer posted revenue of $23.5 million in the period, which topped Street forecasts. Six analysts surveyed by Zacks expected $21.9 million. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 22 cents per share. The drug developer posted revenue of $48.1 million in the period, also exceeding Street forecasts. Four analysts surveyed by Zacks expected $45.8 million.

Chemours last released its quarterly earnings results on May 5th, 2020. The specialty chemicals company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.46 by $0.25. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.33 billion. Its

Invesco S&P SmallCap Health Care ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new May 15th contracts and identified one put and one call contract of particular interest. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ARWR is -4.24 vs. an industry ratio of 1.80. Fifth Street Senior Floating Rate Corp. ( FSFR ) is reporting for the Analysts forecast that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report sales of $36.63 million for the current quarter, according to Zacks. Four analysts have provided estimates for Arrowhead Pharmaceuticals' earnings, with estimates ranging from $20.00 million to $64.50 million. Arrowhead Pharmaceuticals posted sales of $34.66 million during the same quarter last year, which would

Why Arrowhead Pharmaceuticals Shares Dropped 15% in ...

15 Apr 2020 Some analyst calls cover stocks to buy while others cover stocks to sell or Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) was raised to Cardinal Health Inc. (NYSE: CAH) was named as the Bull of the Day at Zacks, 

Zacks Investment Research Page 3 In September 2019 ARWR announced positive topline data from Phase I studies of ARO-APOC3 and ARO-ANG3. Presented at The Global Summit on Cardiology and Heart Diseases in Dubai, the data provided the first substantive look at safety and target activity in the clinical setting and results appear to

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, Quote ...

It hasn't been the best quarter for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders, since the share price has fallen 23% in that time.But that doesn't displace its brilliant

Find the latest Earnings Report Date for Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR) ARWR Arrowhead Pharmaceuticals, Inc. Common Stock. Zacks Investment Research. Find the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock quote, history, news and other vital information to help you with your stock trading and investing. ARWR | Complete Arrowhead Pharmaceuticals Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. NASDAQ:ARWR Arrowhead Pharmaceuticals Stock Price, Forecast & News $32.01-0.76 (-2.32 %) Fundamental company data provided by Morningstar and Zacks Investment Find the latest analyst research for Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR) ZACKS SMALL CAP; Based on analysts offering 12 month price targets for ARWR in the last 3 months.

盛宝交易员委员会 - Proudly Powered by WordPress
Theme by Grace Themes